TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02232191: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Sponsor: University of California, Davis · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 75 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT02232191 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02232191 Rescue Dossier →